SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Recruiting · NCT06889649 · Registry updated 2025-03-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC | Immunotherapy; Radiation Therapy; Renal Cancer Metastatic; Targeted Therapy | Recruiting | Phase 2 | 2025-03-21 | NCT06889649 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking University First Hospital | 225 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking University First Hospital | Beijing | China | 163 |